Kite Pharma, Inc. (KITE): Roy Doumani , director of Kite Pharma, Inc. sold 14,000 shares on Jun 6, 2016. The Insider selling transaction was reported by the company on Jun 8, 2016 to the Securities and Exchange Commission. The shares were sold at $58.06 per share for a total value of $812,581.00 , the company said in a SEC Form 4 Filing.
Other Insider transactions have been reported by the company according to SEC Form 4, on Jun 2, 2016, Jeffrey Wiezorek (SVP Clinical Development) sold 3,000 shares at $51.04 per share price.On Apr 6, 2016, Cynthia M Butitta (COO and CFO) sold 10,000 shares at $50.00 per share price.Also, On Mar 17, 2016, Rizwana F Sproule (VP Regulatory Affairs) sold 8,500 shares at $46.58 per share price.On Mar 17, 2016, Margo R Roberts (Chief Scientific Officer) sold 8,506 shares at $46.40 per share price.
Shares of Kite Pharma Inc (KITE) ended Tuesday, Jun 7, 2016 session in red amid volatile trading. The shares closed down -1.36 points or -2.37% at $56.06 with 8,93,114 shares getting traded. Post opening the session at $57.41, the shares hit an intraday low of $55.45 and an intraday high of $57.91 and the price vacillated in this range throughout the day. The company has a market cap of $2,754 M and the number of outstanding shares has been calculated to be 4,91,29,352 shares. The 52-week high of Kite Pharma Inc is $89.84 and the 52-week low is $38.41.
Company has been under the radar of several Street Analysts.Kite Pharma Inc is Initiated by Raymond James to Outperform and the brokerage firm has set the Price Target at $61. The Rating was issued on Jun 2, 2016.Kite Pharma Inc is Reiterated by Mizuho to Buy while Lowering the Price Target of the company shares to $ 80 from a previous price target of $90 . The Rating was issued on May 10, 2016.
Kite Pharma Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of cancer immunotherapy products to eradicate cancer cells. The Company does this using its engineered autologous cell therapy (eACT) which is an approach to the treatment of cancer. eACT involves the genetic engineering of T cells to express either chimeric antigen receptors (CARs) or T cell receptors (TCRs). It is conducting a Phase II clinical trial of a TCR-based therapy and multiple Phase I-IIa clinical trials of CAR- and TCR-based therapies. The Company’s lead product candidate KTE-C19 is a CAR-based therapy for the treatment of refractory diffuse large B cell lymphoma (DLBCL) primary mediastinal B cell lymphoma (PMBCL) and transformed follicular lymphoma (TFL). It is developing a pipeline of eACT-based product candidates for the treatment of advanced solid and hematological malignancies: CD19CAR KTE-C19CAR and EGFRvlll CAR among others.